Therapeutic agent for iNOS generating illness cross-references to related applications
A therapeutic agent which removes or neutralizes iNOS in the blood of a mammalian subject. The agent may be in the form of an anti-iNOS monoclonal antibody or an iNOS binding entity.
1 . A therapeutic agent for the treatment of an illness in a mammalian subject generating hiNOS in its blood,
comprising:
a monoclonal antibody recognizing human iNOS.
2 . The agent of claim 1 in which said monoclonal antibody recognizing human iNOS comprises a monoclonal antibody neutralizing a cellular effect caused by a form of hiNOS, and the form of hiNOS is selected from the group consisting essentially of:
particulate hiNOS, fragments of particulate hiNOS, vesicle associated hiNOS, vesicle associated fragments of particulate hiNOS, particulate hiNOS associated with another protein, and fragments of particulate hiNOS associated with another protein.
3 . The agent of claim 2 in which the illness is selected from the group consisting essentially of: systemic inflammatory response syndrome, sepsis, severe sepsis, and septic shock.
4 . The agent of claim 2 in which said monoclonal antibody is selected from the group consisting essentially of mouse anti-hiNOS monoclonal antibody, mouse-human chimeric anti-hiNOS monoclonal antibody, humanized anti-hiNOS monoclonal antibody, and human anti-hiNOS monoclonal antibody.
5 . A therapeutic device for the treatment of an illness in a mammalian subject generating hiNOS in its blood,
comprising:
a device coated with a monoclonal antibody recognizing human iNOS.
6 . The agent of claim 5 in which said monoclonal antibody recognizing human iNOS comprises a monoclonal antibody neutralizing a cellular effect caused by a form of hiNOS, and the form of hiNOS is selected from the group consisting essentially of:
particulate hiNOS, fragments of particulate hiNOS, vesicle associated hiNOS, vesicle associated fragments of particulate hiNOS, particulate hiNOS associated with another protein, and fragments of particulate hiNOS associated with another protein.
7 . The agent of claim 6 in which the illness is selected from the group consisting essentially of: systemic inflammatory response syndrome, sepsis, severe sepsis, and septic shock.
8 . The agent of claim 5 in which said monoclonal antibody is selected from the group consisting essentially of mouse anti-hiNOS monoclonal antibody, mouse-human chimeric anti-hiNOS monoclonal antibody, humanized anti-hiNOS monoclonal antibody, and human anti-hiNOS monoclonal antibody.
9 . A therapeutic agent for the treatment of an illness in a mammalian subject generating iNOS in its blood,
comprising:
a hiNOS binding entity.
10 . The therapeutic agent of claim 9 in which said iNOS binding entity is selected from the group consisting essentially of: iNOS binding aptmers, oligionucleotides, artificial antibodies, phage displayed antibodies, phage displayed antibody fragments, and single-chain monoclonal antibodies.
11 . The agent of claim 9 in which said hiNOS binding entity comprises a hiNOS binding entity neutralizing a cellular effect caused by a form of hiNOS and the form of hiNOS is selected from the group consisting essentially of:
particulate hiNOS, fragments of particulate hiNOS, vesicle associated hiNOS, vesicle associated fragments of particulate hiNOS, particulate hiNOS associated with another protein, and fragments of particulate hiNOS associated with another protein.
12 . The agent of claim 9 in which the illness is selected form the group consisting essentially of: systemic inflammatory response syndrome, sepsis, severe sepsis, and septic shock.
13 . A therapeutic device for the treatment of an illness in a mammalian subject generating hiNOS in its blood,
comprising:
a device coated with a hiNOS binding entity.
14 . The agent of claim 13 in which said hiNOS binding entity comprises a hiNOS binding entity neutralizing a cellular effect caused by a form of hiNOS and the form of hiNOS is selected from the group consisting essentially of:
particulate hiNOS, fragments of particulate hiNOS, vesicle associated hiNOS, vesicle associated fragments of particulate hiNOS, particulate hiNOS associated with another protein, and fragments of particulate hiNOS associated with another protein.
15 . The agent of claim 13 in which the illness is selected from the group consisting essentially of: systemic inflammatory response syndrome, sepsis, severe sepsis, and septic shock.
16 . A system for diagnosing an illness in mammalian subjects generating iNOS in the blood,
comprising:
an immunostained iNOS form.
17 . The system of claim 16 in which said immunostained iNOS form comprises extracellular vesicle associated iNOS.
18 . The agent of claim 17 in which the illness is selected from the group consisting essentially of: systemic inflammatory response syndrome, sepsis, severe sepsis, and septic shock.
19 . A therapeutic agent for the treatment of an illness in a mammalian subject generating hiNOS in its blood,
comprising:
an inhibitor of a cellular effect caused by a form of hiNOS.
20 . The agent of claim 19 in which said inhibitor of a cellular effect caused by a form of hiNOS, and the form of hiNOS is selected from the group consisting essentially of:
particulate hiNOS, fragments of particulate hiNOS, vesicle associated hiNOS, vesicle associated fragments of particulate hiNOS, particulate hiNOS associated with another protein, and fragments of particulate hiNOS associated with another protein.
21 . The agent of claim 19 in which said inhibitor of a cellular effect caused by a form of hiNOS comprises a supernatant fraction of hiNOS derived from a cell lysate product of cell lysis.